News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Jaguar Health, Inc. to discuss updates on cancer supportive care portfolio in investor webcast, focusing on CTD and oral mucositis. Details on pivotal phase 3 OnTarget trial for crofelemer -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
Jaguar announces expansion of out-licensing agreement with Magdalena Biosciences for Botanical Drug Candidate targeting schizophrenia market. Company to present at Lytham Partners Spring 2024 Investor Conference
